Literature DB >> 25523130

Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease.

Yalcin Solak1, Seyyid Bilal Acikgoz, Mehmet Yildirim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25523130     DOI： 10.1007/s40261-014-0262-6

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  2 in total

1.  Colchicine toxicity in end-stage renal disease patients: a case-control study.

Authors:  Yalcin Solak; Huseyin Atalay; Zeynep Biyik; Hayrudin Alibasic; Abduzhappar Gaipov; Figen Guney; Adem Kucuk; Halil Zeki Tonbul; Mehdi Yeksan; Suleyman Turk
Journal:  Am J Ther       Date:  2014 Nov-Dec       Impact factor: 2.688

2.  Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease.

Authors:  Suman Wason; David Mount; Robert Faulkner
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859
  2 in total
  1 in total

1.  Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens.

Authors:  Eleni Karatza; George Ismailos; Vangelis Karalis
Journal:  Xenobiotica       Date:  2021-04-12       Impact factor: 1.908
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.